2nd Quarter - Report
LYMPHOMA RESEARCH FOUNDATION for LYMPHOMA RESEARCH FOUNDATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Client
Income
—
Expenses
$6,629
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 19, 2016 | $6,629 | Replaced |
| 2nd Quarter - Amendment | Aug 30, 2016 | $6,629 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBIN R LEVY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.